论文部分内容阅读
目的探讨沙利度胺联合依托泊苷加顺铂(EP)方案化疗对广泛期小细胞肺癌患者血浆血管内皮生长因子(VEGF)水平的影响。方法选取2012年6月—2013年11月收治的广泛期小细胞肺癌患者70例,将所有患者随机分为两组,每组35例。对照组采用单纯EP方案化疗,观察组在对照组治疗的基础上联合沙利度胺治疗,两组患者均连续治疗2个周期,每个周期为28 d。对比两组治疗前后血浆VEGF水平及临床疗效、不良反应发生率、3年内生存率。结果治疗前,两组患者血浆VEGF水平比较,差异无统计学意义(P>0.05);治疗后,观察组血浆VEGF水平低于对照组,差异有统计学意义(P<0.05);两组治疗有效率比较,差异无统计学意义(P>0.05);观察组不良反应发生率低于对照组,3年生存率明显高于对照组,差异均有统计学意义(P<0.05)。结论沙利度胺联合EP方案化疗可有效降低广泛期小细胞肺癌患者血浆VEGF水平,减少不良反应发生率,提高生存率,安全性高。
Objective To investigate the effect of thalidomide combined with etoposide plus cisplatin (EP) on plasma vascular endothelial growth factor (VEGF) levels in patients with extensive stage small cell lung cancer. Methods Seventy patients with extensive stage of small cell lung cancer admitted from June 2012 to November 2013 were selected and all patients were randomly divided into two groups of 35 cases. The control group was treated with simple EP regimen. The observation group was treated with thalidomide on the basis of the control group. Both groups were treated continuously for 2 cycles, each of 28 days. Before and after treatment, the plasma VEGF levels and clinical efficacy, incidence of adverse reactions, and 3-year survival rate were compared. Results Before treatment, there was no significant difference in plasma VEGF between the two groups (P> 0.05). After treatment, the plasma VEGF level in the observation group was lower than that in the control group (P <0.05) (P> 0.05). The incidence of adverse reactions in the observation group was lower than that in the control group, and the 3-year survival rate was significantly higher than that in the control group (P <0.05). Conclusions Thalidomide combined with EP regimen can effectively reduce the plasma VEGF level in patients with extensive stage small cell lung cancer, reduce the incidence of adverse reactions and improve the survival rate and safety.